What's in Bristol-Myers Squibb Co.'s pipeline?

Bristol-Myers Squibb Co. has 314 drugs in our index: 78 marketed, 0 filed, 54 in Phase 3, 59 in Phase 2, 121 in Phase 1.

Which companies overlap with Bristol-Myers Squibb Co.'s portfolio?

Top competitors by shared drug class: , GlaxoSmithKline, Pfizer, Merck Sharp & Dohme LLC, Hoffmann-La Roche.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/bristol-myers-squibb.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Bristol-Myers Squibb Co. — Portfolio Competitive Intelligence Brief

Bristol-Myers Squibb Co. (BMY) pipeline: 78 marketed, 0 filed, 54 Phase 3, 59 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

BMY (NYSE) 78 marketed 0 filed 54 Phase 3 59 Phase 2 121 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Camzyos	MAVACAMTEN	marketed	Cardiac Myosin Inhibitor [EPC]	cardiac myosin	Cardiovascular	2022-01-01
Krazati	ADAGRASIB	marketed		GTPase KRas	Oncology	2022-01-01
Sotyktu	DEUCRAVACITINIB	marketed	Tyrosine Kinase 2 Inhibitor [EPC]	Non-receptor tyrosine-protein kinase TYK2	Immunology	2022-01-01
Zeposia	OZANIMOD	marketed	Sphingosine 1-phosphate Receptor Modulator	Sphingosine 1-phosphate receptor 1	Immunology	2020-01-01
Inrebic	FEDRATINIB HYDROCHLORIDE	marketed		JAK2, FLT3	Oncology	2019-01-01
Inrebic	FEDRATINIB	marketed		Cyclin-G-associated kinase	Oncology	2019-01-01
Idhifa	ENASIDENIB	marketed	Isocitrate Dehydrogenase 2 Inhibitor	Isocitrate dehydrogenase [NADP], mitochondrial	Oncology	2017-01-01
Huluc63	elotuzumab	marketed	SLAMF7-directed Immunostimulatory Antibody [EPC]	SLAM family member 7	Oncology	2015-01-01
Daklinza	DACLATASVIR	marketed	Hepatitis C Virus NS5A Inhibitor	Potassium voltage-gated channel subfamily H member 2	Oncology	2015-01-01
Opdivo	nivolumab	marketed	Programmed Death Receptor-1 Blocking Antibody [EPC]	Programmed cell death protein 1	Oncology	2014-01-01
Pomalyst	pomalidomide	marketed	Thalidomide Analog [EPC]	Protein cereblon	Oncology	2013-01-01
Eliquis	apixaban	marketed	Factor Xa inhibitor	Factor Xa (FXa)	Cardiovascular	2012-01-01

Therapeutic area mix

Oncology · 50
Immunology · 30
Infectious Disease · 14
Infectious Disease / Virology · 12
Other · 11
Cardiovascular · 9
Virology / Hepatology · 5
Neuroscience · 4
Neurology · 3
Diabetes · 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2026-05-21 — Acetadote · 8148356 · Formulation · US
2029-05-14 — Vidaza · 12053482 · Method of Use · US
2029-05-14 — Vidaza · 11571436 · Formulation · US
2030-06-03 — Vidaza · 8846628 · Formulation · US
2031-07-21 — Acetadote · 9327028 · Method of Use · US
2032-04-06 — Acetadote · 8722738 · Method of Use · US
2032-05-08 — Acetadote · 9561204 · Method of Use · US
2032-05-08 — Acetadote · 9427421 · Formulation · US
2032-05-08 — Acetadote · 8747894 · Formulation · US

Competitive overlap (companies sharing drug classes)

· 12 shared drug classes
GlaxoSmithKline · 11 shared drug classes
Pfizer · 11 shared drug classes
Merck Sharp & Dohme LLC · 9 shared drug classes
Hoffmann-La Roche · 7 shared drug classes
Sanofi · 7 shared drug classes
Bayer · 5 shared drug classes
Novartis · 5 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Bristol-Myers Squibb Co.:

Cite this brief

Drug Landscape (2026). Bristol-Myers Squibb Co. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bristol-myers-squibb. Accessed 2026-05-16.